Tracked deals
5
5 tracked deals across 2021-2025.
Operating Company
Healthcare
Essential Pharma
Egham, Surrey, United Kingdom
International specialty pharmaceutical company dedicated to maintaining access to clinically differentiated, niche medicines in small patient populations. Portfolio focuses on CNS, gastroenterology, ophthalmology, and rare disease; acquires low-volume, difficult-to-manufacture therapeutic products and late-stage clinical development assets and focuses on acquiring mature, established branded medicines at risk of shortage or discontinuation to ensure continued supply in more than 70 countries.
- Focus Areas
- Specialty pharmaceuticals, Branded medicines, CNS / Psychiatric therapeutics
- Website
- essentialpharmagroup.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
2 buyout · 2 divestiture · 1 addon
Essential Pharma Acquisition Volume by Year
Last 4 years
Supporting Data
Recent Transactions
-
February 3, 2025
- Buyer
- PRN Physician Recommended Nutriceuticals, Acumen Health Holdings
- Target
- EyePromise
- Industry
- Healthcare Services
- Location
- Missouri, United States
- Type
- Buyout
PRN Physician Recommended Nutriceuticals, part of Acumen Health Holdings, has acquired EyePromise, a Chesterfield, Missouri-based maker of scientifically supported eye vitamins and ocular health products. The acquisition combines PRN’s anterior eye expertise with EyePromise’s posterior eye products to create a more comprehensive eye-health offering for practitioners and patients.
-
- Buyer
- Essential Pharma
- Target
- Reminyl (galantamine hydrobromide) oral capsules
- Seller
- Janssen Pharmaceutica NV, Johnson & Johnson
- Industry
- Pharmaceuticals
- Location
- Antwerp, Belgium
- Type
- Divestiture
Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide) oral capsules from Janssen Pharmaceutica NV (a Johnson & Johnson company). The deal transfers rights in the EEA, South Korea, Thailand and other current markets (excluding the UK & Ireland, Japan and Latin America), expanding Essential Pharma’s CNS portfolio and its presence in the Asia‑Pacific region.
-
April 2, 2024
- Buyer
- Essential Pharma
- Target
- Renaissance Pharma Ltd
- Industry
- Pharmaceuticals
- Location
- Greater Manchester, United Kingdom
- Type
- Buyout
Essential Pharma has completed the acquisition of all issued share capital of Renaissance Pharma Ltd, gaining the clinical-stage immunotherapy Hu14.18K322A (Hu14.18) for treatment of high‑risk neuroblastoma. The deal adds a development‑stage rare disease oncology asset to Essential Pharma's portfolio; Renaissance's CEO Simon Ball and members of the Renaissance team will continue to work with Essential on further development in partnership with St. Jude Children's Research Hospital.
-
- Buyer
- Essential Pharma, Gyrus Capital
- Target
- HALDOL (haloperidol), HALDOL Decanoate (haloperidol decanoate)
- Seller
- Janssen Pharmaceutica NV
- Industry
- Pharmaceuticals
- Location
- Antwerp, Belgium
- Type
- Divestiture
Gyrus Capital-backed Essential Pharma has acquired global rights to HALDOL (haloperidol) and HALDOL Decanoate from Janssen Pharmaceutica NV. The deal expands Essential Pharma's specialty CNS portfolio and secures continued global supply of this WHO-listed essential antipsychotic marketed in the US and more than 60 countries.
-
December 21, 2021
- Buyer
- Essential Pharma, Rosemont Pharmaceuticals Limited
- Target
- Yorkdale Pharma Limited, Essential Pharma Liquids Limited, Two product rights from Novartis (ocular and postpartum therapies)
- Seller
- Rosemont Pharmaceuticals Limited, Essential Pharma, Novartis
- Industry
- Pharmaceuticals
- Location
- United Kingdom
- Type
- Addon
Gyrus Capital‑backed Essential Pharma completed a refinancing and executed a series of portfolio transactions in December 2021. Essential Pharma acquired Yorkdale Pharma Limited from Rosemont Pharmaceuticals, divested its 14‑product oral liquid portfolio (Essential Pharma Liquids Limited) to Rosemont, and also acquired worldwide (ex‑US, ex‑India) rights to two products from Novartis to expand its global specialty pharmaceutical portfolio.
Related Acquisition Pages
Selling a company? Get in front of buyers like Essential Pharma
Turn tracked acquisition activity into an outreach-ready buyer list.